These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 30229336

  • 1. Substantial renal conversion of L-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension.
    Lamotte G, Holmes C, Sullivan P, Goldstein DS.
    Clin Auton Res; 2019 Feb; 29(1):113-117. PubMed ID: 30229336
    [Abstract] [Full Text] [Related]

  • 2. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R.
    Circulation; 2003 Aug 12; 108(6):724-8. PubMed ID: 12885750
    [Abstract] [Full Text] [Related]

  • 3. Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS.
    Goldstein DS, Holmes C, Sewell L, Pechnik S, Kopin IJ.
    J Clin Pharmacol; 2011 Jan 12; 51(1):66-74. PubMed ID: 20220040
    [Abstract] [Full Text] [Related]

  • 4. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug.
    Goldstein DS.
    Cardiovasc Drug Rev; 2006 Jan 12; 24(3-4):189-203. PubMed ID: 17214596
    [Abstract] [Full Text] [Related]

  • 5. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, Taylor MD.
    Clin Auton Res; 2001 Aug 12; 11(4):235-42. PubMed ID: 11710796
    [Abstract] [Full Text] [Related]

  • 6. The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors.
    Kaufmann H.
    J Neural Transm Suppl; 2006 Aug 12; (70):477-84. PubMed ID: 17017570
    [Abstract] [Full Text] [Related]

  • 7. DL-Threo-3,4-dihydroxyphenylserine does not exert a pressor effect in orthostatic hypotension.
    Hoeldtke RD, Cilmi KM, Mattis-Graves K.
    Clin Pharmacol Ther; 1984 Sep 12; 36(3):302-6. PubMed ID: 6432398
    [Abstract] [Full Text] [Related]

  • 8. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure.
    Goldstein DS, Holmes C, Kaufmann H, Freeman R.
    Clin Auton Res; 2004 Dec 12; 14(6):363-8. PubMed ID: 15666063
    [Abstract] [Full Text] [Related]

  • 9. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
    Kaufmann H.
    Clin Auton Res; 2008 Mar 12; 18 Suppl 1():19-24. PubMed ID: 18368303
    [Abstract] [Full Text] [Related]

  • 10. Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde.
    Holmes C, Whittaker N, Heredia-Moya J, Goldstein DS.
    Clin Chem; 2010 May 12; 56(5):832-8. PubMed ID: 20207766
    [Abstract] [Full Text] [Related]

  • 11. [Development of L-threo-DOPS, a norepinephrine precursor amino acid].
    Katsube J, Narabayashi H, Hayashi A, Tanaka C, Suzuki T.
    Yakugaku Zasshi; 1994 Nov 12; 114(11):823-46. PubMed ID: 7853146
    [Abstract] [Full Text] [Related]

  • 12. Treatment of orthostatic hypotension in Shy-Drager syndrome with DL-threo-3,4-dihydroxyphenylserine: a case report.
    Sakoda S, Suzuki T, Higa S, Ueji M, Kishimoto S, Matsumoto M, Yoneda S.
    Eur Neurol; 1985 Nov 12; 24(5):330-4. PubMed ID: 3932074
    [Abstract] [Full Text] [Related]

  • 13. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H.
    Neurology; 2018 Oct 16; 91(16):e1539-e1544. PubMed ID: 30232253
    [Abstract] [Full Text] [Related]

  • 14. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.
    Birkmayer W, Birkmayer G, Lechner H, Riederer P.
    J Neural Transm; 1983 Oct 16; 58(3-4):305-13. PubMed ID: 6420517
    [Abstract] [Full Text] [Related]

  • 15. The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients.
    Tohgi H, Abe T, Takahashi S.
    J Neural Transm Park Dis Dement Sect; 1993 Oct 16; 5(1):27-34. PubMed ID: 8439390
    [Abstract] [Full Text] [Related]

  • 16. Effects of L-threo-3,4-dihydroxyphenylserine on orthostatic hypotension in hemodialysis patients.
    Iida N, Koshikawa S, Akizawa T, Tsubakihara Y, Marumo F, Akiba T, Kawaguchi Y, Imada A, Yamazaki C, Suzuki M.
    Am J Nephrol; 2002 Oct 16; 22(4):338-46. PubMed ID: 12169865
    [Abstract] [Full Text] [Related]

  • 17. Effect of a synthetic norepinephrine precursor, L-threo-3,4- dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients.
    Tohgi H, Abe T, Takahashi S, Takahashi J, Ueno M, Nozaki Y.
    Neurosci Lett; 1990 Aug 14; 116(1-2):194-7. PubMed ID: 2259448
    [Abstract] [Full Text] [Related]

  • 18. The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial.
    Freeman R, Landsberg L, Young J.
    Neurology; 1999 Dec 10; 53(9):2151-7. PubMed ID: 10599797
    [Abstract] [Full Text] [Related]

  • 19. Diuretic effects of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in anesthetized rats.
    Morimoto S, Matsumura Y, Ohyama T, Shinyama H, Ichihara T, Takahashi Y, Hisaki K.
    Jpn J Pharmacol; 1990 Mar 10; 52(3):431-9. PubMed ID: 2110272
    [Abstract] [Full Text] [Related]

  • 20. d,l-threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine beta-hydroxylase deficiency.
    Man in 't Veld AJ, Boomsma F, van den Meiracker AH, Julien C, Lenders J, Schalekamp MA.
    J Hypertens Suppl; 1988 Dec 10; 6(4):S547-9. PubMed ID: 3149290
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.